… examined the efficacy of IFN as a treatment for severe SARS-COV-2, particularly with …
treatment administration ranged from 3 to 14 days, while only 4 of the 11 studies administered IFN …

… Given that interferon stimulated gene expression peaks between 2 and 4 h post administration,
in this study all groups receiving IFNb treatments were started on treatment 2 h prior to …

… coronavirus (SARS-CoV) infection. We assessed the antiviral potential of recombinant interferons
against two clinical isolates of SARS-CoV—FFM… Interferon β was five to ten times more …

… antivirals to curtail the COVID-19 pandemic. Herein, we report the sensitivity of SARS-CoV-2
to recombinant human interferons α and β (IFNα/β). Treatment with IFN-α or IFN-β at a …

… Overall, sensitivity data suggest 248 that type I IFN treatment may have utility for treating
SARS-CoV-2 if the appropriate parameters 249 can be determined. In addition, use of type III …

… Comparing SARS-CoV-2 and influenza A virus in human … the absence of IFN-I stimulation
by SARS-CoV-2 alone but … IFN-I treatment postinfection and found that SARS-CoV-2 was …

… type I IFN responses in patients with severe COVID-19. Finally, we discuss how delayed
but exaggerated type I IFN … by IFN responses, the use of type I or III IFNs for the treatment of …

… COVID-19 awaits validation. Here, we describe our current knowledge of the complex interplay
between SARS-CoV-2 infection and the IFN … of a well-timed IFN-I treatment and propose …

… that IFN-β treatment effectively blocks SARS-CoV-2 replication. In summary, our study shows
that SARS-CoV-2 … Moreover, we show that SARS-CoV-2 is susceptible to IFN treatment. Our …

… to COVID-19… coronavirus 2 (SARS-CoV-2) suppresses cellular interferon production, thus
limiting the strength of the initial innate immune response. Exogenous use of inhaled interferon …